Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$0.79
+8.8%
$0.70
$0.53
$1.90
$61.41M1.01903,641 shs408,654 shs
Pulmonx Corporation stock logo
LUNG
Pulmonx
$2.78
+2.0%
$3.23
$2.50
$9.37
$111.72M0.45305,628 shs151,836 shs
Nevro Corp. stock logo
NVRO
Nevro
$5.85
+0.1%
$5.85
$3.17
$10.37
$224.32M0.81800,223 shs753,602 shs
Nyxoah SA stock logo
NYXH
Nyxoah
$7.77
+0.9%
$7.24
$5.55
$11.87
$264.65M1.6275,967 shs14,612 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hyperfine, Inc. stock logo
HYPR
Hyperfine
0.00%+6.39%-0.90%+21.35%-21.10%
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.00%+6.73%-12.46%-57.95%-57.24%
Nevro Corp. stock logo
NVRO
Nevro
0.00%0.00%0.00%0.00%-32.10%
Nyxoah SA stock logo
NYXH
Nyxoah
0.00%+4.02%+1.30%+36.08%-0.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hyperfine, Inc. stock logo
HYPR
Hyperfine
1.8641 of 5 stars
3.32.00.00.00.02.50.6
Pulmonx Corporation stock logo
LUNG
Pulmonx
3.0035 of 5 stars
3.33.00.00.02.03.30.6
Nevro Corp. stock logo
NVRO
Nevro
0.1712 of 5 stars
1.00.00.00.00.01.70.6
Nyxoah SA stock logo
NYXH
Nyxoah
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hyperfine, Inc. stock logo
HYPR
Hyperfine
2.67
Moderate Buy$1.0634.35% Upside
Pulmonx Corporation stock logo
LUNG
Pulmonx
2.63
Moderate Buy$11.53315.32% Upside
Nevro Corp. stock logo
NVRO
Nevro
1.92
Reduce$5.36-8.29% Downside
Nyxoah SA stock logo
NYXH
Nyxoah
3.00
Buy$14.5086.62% Upside

Current Analyst Ratings Breakdown

Latest HYPR, NVRO, LUNG, and NYXH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/22/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.15
5/15/2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1.20 ➝ $1.00
5/14/2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$1.29 ➝ $0.68
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.00
5/1/2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/21/2025
Nyxoah SA stock logo
NYXH
Nyxoah
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
4/8/2025
Nyxoah SA stock logo
NYXH
Nyxoah
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hyperfine, Inc. stock logo
HYPR
Hyperfine
$12.89M4.76N/AN/A$0.67 per share1.18
Pulmonx Corporation stock logo
LUNG
Pulmonx
$83.79M1.33N/AN/A$2.17 per share1.28
Nevro Corp. stock logo
NVRO
Nevro
$408.52M0.55N/AN/A$8.10 per share0.72
Nyxoah SA stock logo
NYXH
Nyxoah
$4.89M54.12N/AN/A$3.60 per share2.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-$40.72M-$0.54N/AN/AN/A-343.42%-74.19%-62.40%8/14/2025 (Estimated)
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%8/4/2025 (Estimated)
Nyxoah SA stock logo
NYXH
Nyxoah
-$64.10M-$2.13N/AN/AN/A-1,571.39%-63.37%-46.67%8/5/2025 (Estimated)

Latest HYPR, NVRO, LUNG, and NYXH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.40N/AN/AN/A$23.46 millionN/A
5/14/2025Q1 2025
Nyxoah SA stock logo
NYXH
Nyxoah
-$0.49-$0.63-$0.14-$0.63$1.64 million$1.12 million
5/13/2025Q1 2025
Hyperfine, Inc. stock logo
HYPR
Hyperfine
-$0.12-$0.12N/A-$0.12$2.82 million$2.14 million
5/7/2025Q1 2025
Pulmonx Corporation stock logo
LUNG
Pulmonx
-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hyperfine, Inc. stock logo
HYPR
Hyperfine
N/AN/AN/AN/AN/A
Pulmonx Corporation stock logo
LUNG
Pulmonx
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A
Nyxoah SA stock logo
NYXH
Nyxoah
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hyperfine, Inc. stock logo
HYPR
Hyperfine
N/A
6.07
5.48
Pulmonx Corporation stock logo
LUNG
Pulmonx
0.38
4.97
4.29
Nevro Corp. stock logo
NVRO
Nevro
0.67
5.02
3.76
Nyxoah SA stock logo
NYXH
Nyxoah
0.22
3.59
3.35

Institutional Ownership

CompanyInstitutional Ownership
Hyperfine, Inc. stock logo
HYPR
Hyperfine
15.03%
Pulmonx Corporation stock logo
LUNG
Pulmonx
91.04%
Nevro Corp. stock logo
NVRO
Nevro
95.52%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A

Insider Ownership

CompanyInsider Ownership
Hyperfine, Inc. stock logo
HYPR
Hyperfine
30.98%
Pulmonx Corporation stock logo
LUNG
Pulmonx
6.80%
Nevro Corp. stock logo
NVRO
Nevro
3.20%
Nyxoah SA stock logo
NYXH
Nyxoah
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Hyperfine, Inc. stock logo
HYPR
Hyperfine
19077.83 million53.72 millionOptionable
Pulmonx Corporation stock logo
LUNG
Pulmonx
25040.26 million37.52 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,09038.37 million36.27 millionOptionable
Nyxoah SA stock logo
NYXH
Nyxoah
11034.06 millionN/ANot Optionable

Recent News About These Companies

Brokers Set Expectations for Nyxoah FY2026 Earnings
Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript
Publication relating to transparency notifications

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hyperfine stock logo

Hyperfine NASDAQ:HYPR

$0.79 +0.06 (+8.81%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$0.78 -0.01 (-0.76%)
As of 07/3/2025 04:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors. Hyperfine, Inc. was founded in 2014 and is based in Guilford, Connecticut.

Pulmonx stock logo

Pulmonx NASDAQ:LUNG

$2.78 +0.06 (+2.02%)
As of 07/3/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Nevro stock logo

Nevro NYSE:NVRO

$5.85 +0.01 (+0.10%)
Closing price 04/2/2025
Extended Trading
$5.85 0.00 (0.00%)
As of 04/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Nyxoah stock logo

Nyxoah NASDAQ:NYXH

$7.77 +0.07 (+0.91%)
Closing price 07/3/2025 12:59 PM Eastern
Extended Trading
$7.57 -0.20 (-2.59%)
As of 07/3/2025 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.